Table 1.
Demographic and Clinical Characteristics of 293 Patients
| Characteristic | Variable | Value |
|---|---|---|
| KPS | <80 | 33 (11.3%) |
| ≥80 | 260 (88.7%) | |
| Fuhrman grade | 1 | 3 (1.0%) |
| 2 | 27 (9.3%) | |
| 3 | 116 (39.9%) | |
| 4 | 145 (49.8%) | |
| Unknown | 2 | |
| RCC histology | Clear | 261 (90.9%) |
| Papillary | 26 (9.1%) | |
| Unknown | 6 | |
| AJCC tumor stage | T3a | 84 (28.7%) |
| T3b | 137 (46.8%) | |
| T3c | 34 (11.6%) | |
| T4 | 38 (13.0%) | |
| AJCC node stage | pN negative | 68 (52.8%) |
| pN positive | 119 (47.2%) | |
| Unknown | 106 | |
| Sarcomatoid features | No | 236 (80.8%) |
| Yes | 56 (19.2%) | |
| Unknown | 1 | |
| Rhabdoid features | No | 278 (94.9%) |
| Yes | 15 (5.1%) | |
| Tumor Necrosis | No | 77 (29.2%) |
| Yes | 187 (70.9%) | |
| Unknown | 29 | |
| Soft tissue margin positive | No | 265 (90.4%) |
| Yes | 28 (9.6%) | |
| No. of metastases | 1 | 171 (62.0%) |
| ≥2 | 105 (38.0%) | |
| Unknown | 17 | |
| Lung metastases | No | 107 (36.5%) |
| Yes | 186 (63.5%) | |
| Bone metastases | No | 238 (81.5%) |
| Yes | 54 (18.5%) | |
| Brain metastases | No | 283 (96.6%) |
| Yes | 10 (3.4%) | |
| Liver metastases | No | 258 (88.1%) |
| Yes | 35 (11.9%) | |
| MSKCC prognostic model | Favorable | 62 (21.2%) |
| Intermediate | 148 (50.7%) | |
| Poor | 82 (28.1%) | |
| Unknown | 1 | |
| Age (years) | Mean | 61.64 |
| Median | 61 | |
| Minimum | 24.10 | |
| Maximum | 86.30 | |
| SD | 10.62 | |
| Unknown | 4 | |
| Charlson comorbidity index | Mean | 7.39 |
| Median | 8 | |
| Minimum | 1 | |
| Maximum | 14 | |
| SD | 2.21 | |
| Unknown | 74 |
Abbreviations: AJCC = American Joint Committee on Cancer; KPS = Karnofsky performance status; MSKCC = Memorial Sloan Kettering Cancer Center; pN = pathologic node stage; RCC = renal-cell carcinoma; SD = standard deviation.